HURA
NASDAQTuHURA Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News25/Ratings4
News · 26 weeks40+20%
2025-12-072026-05-31
Mix1890d
- SEC Filings10(56%)
- Other4(22%)
- Offering1(6%)
- Leadership1(6%)
- Analyst1(6%)
- Insider1(6%)
Latest news
25 items- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- INSIDERChief Executive Officer Bianco James A. gifted 150,000 shares, decreasing direct ownership by 6% to 2,173,307 units (SEC Form 4)4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)
- SECSEC Form 10-Q filed by TuHURA Biosciences Inc.10-Q - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- PRTuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateTAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's first quarter ended March 31, 2026, and provided a corporate update."I am very pleased with the progress we have made this past quarter as we continue to execute upon our corporate and development strategy. Importantly, we recently established a $50 million non-equity-based source of operating capital in the form of credit facility with our largest stockholder on attractive terms for the company allowing us to fund operatio
- PRTuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor ConferenceTAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, will participate in a fireside chat, at the 4th Annual H.C. Wainwright BioConnect Investor Conference taking place in New York City.4th Annual H.C. Wainwright BioConnect Investor ConferenceDate: Tuesday, May 19, 2026Time: 2:00 pm ETLinks: To register and view presentation, click HERE.A live and archived webcast of the presentation will also be available through the investors page of TuHU
- SECAmendment: SEC Form 8-K/A filed by TuHURA Biosciences Inc.8-K/A - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECAmendment: SEC Form 10-K/A filed by TuHURA Biosciences Inc.10-K/A - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- ANALYSTCitizens initiated coverage on TuHURA Biosciences with a new price targetCitizens initiated coverage of TuHURA Biosciences with a rating of Mkt Outperform and set a new price target of $9.00
- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- PRTuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement milestonesTAMPA, Fla., April 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a loan agreement providing a credit facility of up to $50 million in funding to support the Company's pipeline, ongoing clinical trials, and general corporate expenses. The lender is an affiliate of the Company's largest stockholder, K&V Investment One LLC.Under the terms of the
- SECSEC Form 424B5 filed by TuHURA Biosciences Inc.424B5 - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECSEC Form 8-K filed by TuHURA Biosciences Inc.8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- PRTuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical OperationsMrs. Garofalo brings over 20 years of experience in Phase I-IV drug and biologic developmentTAMPA, Fla., April 7, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Amanda Garofalo, MSHS, as Senior Vice President (SVP) of Clinical Operations.Mrs. Garofalo, who brings over 20 years of clinical and development experience, will work closely with Craig Tendler, M.D., and oversee day-to-day clinical operations."We warmly welcome Amanda to the TuHURA team," said James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosc
- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- PRTuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateTAMPA, Fla., April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's fourth quarter and full year ended December 31, 2025, and provided a corporate update."2025 was a strong year of executing upon our goals, and we continue to move all our programs forward this year. As we progress our clinical development pipeline, we have strategically strengthened our clinical and drug development expertise with Craig Tendler, M.D., providing the strategic and operational services consistent with those o
- SECSEC Form 10-K filed by TuHURA Biosciences Inc.10-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- PRCraig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related CancersDistinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than $16 billion in worldwide sales TAMPA, Fla., March 23, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Dr. Craig L. Tendler will provide strat
- PRTuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price RequirementTAMPA, Fla., Feb. 27, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that on February 26, 2026, it received written notice from the Nasdaq Stock Market LLC (Nasdaq) confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the "Listing Rule"). Nasdaq confirmed that for the last 11 consecutive business days, from February 10, 2026, through February 25, 2026, the closing bid price of the Company's common stock has been at $1.00 per share or grea
- PRTuHURA Biosciences Announces Participation in Upcoming Investor ConferencesTAMPA, Fla., Feb. 24, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that Dr. James Bianco, President and Chief Executive Officer, will participate in the following upcoming investor conferences:Citizens Life Science ConferenceDate: Tuesday, March 10, 2026Time: 4:00 pm ETLinks: To register and view presentation, click HERE. A live and archived webcast of the presentation will also be available through the investors page of TuHURA's corporate website at https://ir.tuhurabio.com/news-events/events.Leerink Global Healthcare Con
- INSIDERSEC Form 4 filed by Director Tendler Craig4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)
- INSIDERSEC Form 4 filed by Director Ng George K4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)
- SECSEC Form SCHEDULE 13G filed by TuHURA Biosciences Inc.SCHEDULE 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)
- INSIDERSEC Form 4 filed by Director Manuso James S J4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)
- INSIDERSEC Form 4 filed by Director List Alan4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)
HURA FAQ
5 questionsWhere does HURA stock trade?
TuHURA Biosciences Inc. (HURA) is listed on NASDAQ.What sector and industry is HURA in?
TuHURA Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about HURA?
TuHURA Biosciences Inc. has had 4 recent analyst actions on file. The most recent action was from Citizens: Mkt Outperform with a $900.00 price target on 2026-04-27. Recent price targets range from $900.00 to $1500.00.What companies are similar to HURA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare HURA side-by-side with any of them on Quantisnow.How can I track HURA on Quantisnow?
Quantisnow aggregates TuHURA Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HURA to receive live email and push alerts on every new disclosure.